Two more weeks to go!

There are two weeks left in Injeq’s share issue. Read the promising news and invest:

Funding: Injeq Oyj (


The way to go to the German market

A major neurological research hospital in Erlangen has expressed their interest to study lumbar punctures with Injeq IQ Tip system. Discussion has been about comparing Injeq smart needle to the atraumatic needle that is commonly used in Erlangen. So far, in earlier Injeq studies the observations present almost half smaller post puncture headache incidence than lumbar punctures done with atraumatic needles. See the picture.


Progress in FDA Breakthrough Device designation

During July Injeq has discussed with US authorities about Breakthrough Device designation in good spirit. We are expecting the results of the evaluation next week. The designation would ensure smooth processing for the Injeq products’ US market approval. Fingers cross!


Tiedote osakkeenomistajille / Notice to shareholders

Read more »

News release on April 12, 2024

The share issue of Injeq Plc. ended on April 5, 2024, and the investment round did not achieve the goals […]
Read more »

Information to shareholders, March 22nd, 2024

Injeq has started a share issue. The maximum of the financing round is set at €3,000,000. If the €2,000,000 goal […]
Read more »

Injeq webinars by Dr Sauli Palmu and Dr Harri Sievänen

Injeq webinar videos are now available! Welcome to participate in Dr. Sauli Palmu’s lecture “Lumbar punctures in pediatric hemato-oncology” (part […]
Read more »

New distributor agreement with “GENFAX SRL”

We are pleased to announce that GENFAX is appointed as INJEQ’s exclusive distributor in Romania. We are confident that our […]
Read more »

Injeq webinar today, Thursday Feb 22nd, 2024

Welcome to the webinar “Innovation in lumbar punctures” on February 22nd, 2024, at 7:00 pm (Madrid time Zone)   Lecturers […]
Read more »